The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 03, 2026

Filed:

Oct. 01, 2019
Applicants:

Arvinas Operations, Inc., New Haven, CT (US);

Genentech, Inc., South San Francisco, CA (US);

Inventors:

Andrew P. Crew, Guilford, CT (US);

Jing Wang, Milford, CT (US);

Michael Berlin, Flemington, NJ (US);

Peter Dragovich, South San Francisco, CA (US);

Huifen Chen, South San Francisco, CA (US);

Leanna Staben, South San Francisco, CA (US);

Assignees:

Arvinas Operations, Inc., New Haven, CT (US);

Genentech, Inc., South San Francisco, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/427 (2006.01); A61K 31/4035 (2006.01); A61K 31/4245 (2006.01); A61K 31/437 (2006.01); A61K 31/4439 (2006.01); A61K 31/496 (2006.01); A61K 31/541 (2006.01); A61K 47/54 (2017.01);
U.S. Cl.
CPC ...
A61K 31/427 (2013.01); A61K 31/4035 (2013.01); A61K 31/4245 (2013.01); A61K 31/437 (2013.01); A61K 31/4439 (2013.01); A61K 31/496 (2013.01); A61K 31/541 (2013.01); A61K 47/555 (2017.08);
Abstract

The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.


Find Patent Forward Citations

Loading…